Quattro Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Quattro Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,000	Closed	-$1.22M	–	78
2024 Q2	$1.22M	Hold	5,000	–	–	0.32%	45
2024 Q1	$747K	Buy	5,000 +4,809	+2,518%	+$802K	0.21%	51
2023 Q4	$957K	Sell	191 -4,809	-96%	-$819K	0.33%	46
2023 Q3	$886K	Hold	5,000	–	–	0.39%	48
2023 Q2	$950K	Hold	5,000	–	–	0.38%	46
2023 Q1	$1M	Hold	5,000	–	–	0.41%	42
2022 Q4	$1.19M	Buy	+5,000	New	+$1.07M	0.47%	34

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Quattro Financial Advisors's ALNY Position: Q3 2024 in Review

Quattro Financial Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 5,000 shares — an estimated $1.22M sold.

Quattro Financial Advisors first reported a position in ALNY in Q4 2022 and held it in 7 quarters. The position peaked at $1.22M in Q2 2024. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

Quattro Financial Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Quattro Financial Advisors sold 5,000 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $1.22M.
Quattro Financial Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 7 quarters.
Quattro Financial Advisors's Alnylam Pharmaceuticals position peaked at $1.22M in Q2 2024.
567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Quattro Financial Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.